Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Clofibrate | The risk or severity of adverse effects can be increased when Clofibrate is combined with Pemafibrate. |
| Fenofibrate | The risk or severity of adverse effects can be increased when Fenofibrate is combined with Pemafibrate. |
| Gemfibrozil | The risk or severity of adverse effects can be increased when Gemfibrozil is combined with Pemafibrate. |
| Bezafibrate | The risk or severity of adverse effects can be increased when Bezafibrate is combined with Pemafibrate. |
| Etofibrate | The risk or severity of adverse effects can be increased when Etofibrate is combined with Pemafibrate. |
| Ciprofibrate | The risk or severity of adverse effects can be increased when Ciprofibrate is combined with Pemafibrate. |
| Simfibrate | The risk or severity of adverse effects can be increased when Simfibrate is combined with Pemafibrate. |
| Ronifibrate | The risk or severity of adverse effects can be increased when Ronifibrate is combined with Pemafibrate. |
| Aluminium clofibrate | The risk or severity of adverse effects can be increased when Aluminium clofibrate is combined with Pemafibrate. |
| Clofibride | The risk or severity of adverse effects can be increased when Clofibride is combined with Pemafibrate. |
| Fenofibric acid | The risk or severity of adverse effects can be increased when Fenofibric acid is combined with Pemafibrate. |
| Ezetimibe | The serum concentration of Ezetimibe can be increased when it is combined with Pemafibrate. |
| Ursodeoxycholic acid | The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Pemafibrate. |
| Glycochenodeoxycholic Acid | The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Pemafibrate. |
| Cholic Acid | The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Pemafibrate. |
| Glycocholic acid | The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Pemafibrate. |
| Deoxycholic acid | The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Pemafibrate. |
| Taurocholic acid | The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Pemafibrate. |
| Obeticholic acid | The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Pemafibrate. |
| Chenodeoxycholic acid | The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Pemafibrate. |
| Taurochenodeoxycholic acid | The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Pemafibrate. |
| Tauroursodeoxycholic acid | The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Pemafibrate. |
| Bamet-UD2 | The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Pemafibrate. |
| Dehydrocholic acid | The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Pemafibrate. |
| Hyodeoxycholic Acid | The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Pemafibrate. |
| Cyclosporine | The risk or severity of renal failure can be increased when Cyclosporine is combined with Pemafibrate. |
| Glimepiride | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Glimepiride. |
| Acetohexamide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Acetohexamide. |
| Chlorpropamide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Chlorpropamide. |
| Tolazamide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Tolazamide. |
| Glyburide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Glyburide. |
| Glipizide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Glipizide. |
| Gliclazide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Gliclazide. |
| Tolbutamide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Tolbutamide. |
| Gliquidone | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Gliquidone. |
| Glisoxepide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Glisoxepide. |
| Glibornuride | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Glibornuride. |
| Carbutamide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Carbutamide. |
| Metahexamide | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Metahexamide. |
| Colestipol | Colestipol can cause a decrease in the absorption of Pemafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sevelamer | Sevelamer can cause a decrease in the absorption of Pemafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Pemafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Pemafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Pemafibrate is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Pemafibrate is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Pemafibrate is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Pemafibrate is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Pemafibrate is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Pemafibrate is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Pemafibrate is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Pemafibrate is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Pemafibrate is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Pemafibrate is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Pemafibrate is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Pemafibrate is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Pemafibrate is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Pemafibrate is combined with (S)-Warfarin. |
| Tacrolimus | Tacrolimus may increase the nephrotoxic activities of Pemafibrate. |
| Pravastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Pravastatin. |
| Lovastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Lovastatin. |
| Cerivastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Cerivastatin. |
| Simvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Simvastatin. |
| Atorvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Atorvastatin. |
| Fluvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Fluvastatin. |
| Rosuvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Rosuvastatin. |
| Mevastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Mevastatin. |
| Pitavastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Pitavastatin. |
| Insulin human | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin human. |
| Insulin lispro | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin lispro. |
| Insulin glargine | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin glargine. |
| Insulin pork | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin pork. |
| Insulin aspart | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin aspart. |
| Insulin detemir | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin detemir. |
| Insulin glulisine | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin glulisine. |
| NN344 | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with NN344. |
| Insulin beef | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin beef. |
| Insulin degludec | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin degludec. |
| Insulin argine | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin argine. |
| Insulin peglispro | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin peglispro. |
| Insulin tregopil | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin tregopil. |
| Insulin icodec | The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin icodec. |